{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T04:16:20Z","timestamp":1688357780955},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med.","J. Jpn. Soc. Intern. Med"],"published-print":{"date-parts":[[2012]]},"DOI":"10.2169\/naika.101.1994","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T23:02:59Z","timestamp":1373410979000},"page":"1994-2001","source":"Crossref","is-referenced-by-count":0,"title":["1. Novel Molecular Mechanism of Myelodysplastic Syndromes","1\uff0e\u9aa8\u9ac4\u7570\u5f62\u6210\u75c7\u5019\u7fa4\u306e\u65b0\u305f\u306a\u5206\u5b50\u30e1\u30ab\u30cb\u30ba\u30e0"],"prefix":"10.2169","volume":"101","author":[{"given":"Kenichi","family":"Yoshida","sequence":"first","affiliation":[{"name":"Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sanada","sequence":"additional","affiliation":[{"name":"Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Tefferi A, Vardiman JW: Myelodysplastic syndromes. N Engl J Med 361: 1872-1885, 2009.","DOI":"10.1056\/NEJMra0902908"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Yoshida K, et al: Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478: 64-69, 2011.","DOI":"10.1038\/nature10496"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Papaemmanuil E, et al: Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365: 1384-1395, 2011.","DOI":"10.1056\/NEJMoa1103283"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Graubert TA, et al: Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 44: 53-57, 2012.","DOI":"10.1038\/ng.1031"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Malcovati L, et al: Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms. Blood 118: 6239-6246, 2011.","DOI":"10.1182\/blood-2011-09-377275"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Damm F, et al: Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012.","DOI":"10.1182\/blood-2011-12-400994"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Patnaik MM, et al: SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 119: 569-572, 2012.","DOI":"10.1182\/blood-2011-09-377994"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Thol F, et al: Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012.","DOI":"10.1016\/j.yonc.2012.07.010"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Makishima H, et al: Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012.","DOI":"10.1182\/blood-2011-12-399774"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Wang L, et al: SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365: 2497-2506, 2011.","DOI":"10.1056\/NEJMoa1109016"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kaida D, et al: Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 3: 576-583, 2007.","DOI":"10.1038\/nchembio.2007.18"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kotake Y, et al: Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 3: 570-575, 2007.","DOI":"10.1038\/nchembio.2007.16"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Albert BJ, et al: Total syntheses, fragmentation studies, and antitumor\/antiproliferative activities of FR901464 and its low picomolar analogue. J Am Chem Soc 129: 2648-2659, 2007.","DOI":"10.1021\/ja067870m"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/101\/7\/101_1994\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:36:14Z","timestamp":1688344574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/101\/7\/101_1994\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.101.1994","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}